Abstract

Tumor-initiating cells with reprogramming plasticity or stem-progenitor cell properties (stemness) are thought to be essential for cancer development and metastatic regeneration in many cancers; however, elucidation of the underlying molecular network and pathways remains demanding. Combining machine learning and experimental investigation, here we report CD81, a tetraspanin transmembrane protein known to be enriched in extracellular vesicles (EVs), as a newly identified driver of breast cancer stemness and metastasis. Using protein structure modeling and interface prediction-guided mutagenesis, we demonstrate that membrane CD81 interacts with CD44 through their extracellular regions in promoting tumor cell cluster formation and lung metastasis of triple negative breast cancer (TNBC) in human and mouse models. In-depth global and phosphoproteomic analyses of tumor cells deficient with CD81 or CD44 unveils endocytosis-related pathway alterations, leading to further identification of a quality-keeping role of CD44 and CD81 in EV secretion as well as in EV-associated stemness-promoting function. CD81 is co-expressed along with CD44 in human circulating tumor cells (CTCs) and enriched in clustered CTCs that promote cancer stemness and metastasis, supporting the clinical significance of CD81 in association with patient outcomes. Our study highlights machine learning as a powerful tool in facilitating the molecular understanding of new molecular targets in regulating stemness and metastasis of TNBC.

Data availability

RNA sequencing data have been deposited to GEO database with accession number GSE174087.Mass spec raw data sets have been deposited in the Japan ProteOmeSTandard Repository (https://repository.jpostdb.org/) (98). The accession numbers are PXD029529 for ProteomeXchange (99) and JPST001321 for jPOST. The access link is https://repository.jpostdb.org/preview/1370203119618182ba1c0f2

The following data sets were generated

Article and author information

Author details

  1. Erika K Ramos

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    Erika K Ramos, has patents on exosomes which are not related to this manuscript..
  2. Chia-Feng Tsai

    Biological Sciences Division, Pacific Northwest National Laboratory, Richland, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6514-6911
  3. Yuzhi Jia

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  4. Yue Cao

    Department of Electrical and Computer Engineering, Texas A&M University, College Station, United States
    Competing interests
    No competing interests declared.
  5. Megan Manu

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  6. Rokana Taftaf

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  7. Andrew D Hoffmann

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    Andrew D Hoffmann, has patents on exosomes which are not related to the paper..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5479-944X
  8. Lamiaa El-Shennawy

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    Lamiaa El-Shennawy, has patents on exosomes which are not related to the paper..
  9. Marina A Gritsenko

    Biological Science Division, Pacific Northwest National Laboratory, Richland, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9992-9829
  10. Valery Adorno-Cruz

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  11. Emma J Schuster

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    Emma J Schuster, has patents on exosomes which are not related to the paper..
  12. David Scholten

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  13. Dhwani Patel

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  14. Xia Liu

    Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, United States
    Competing interests
    No competing interests declared.
  15. Priyam Patel

    Quantitative Data Science Core, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9433-5017
  16. Brian Wray

    Quantitative Data Science Core, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  17. Youbin Zhang

    Department of Medicine, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  18. Shanshan Zhang

    Pathology Core Facility, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  19. Ronald J Moore

    Biological Sciences Division, Pacific Northwest National Laboratory, Richland, United States
    Competing interests
    No competing interests declared.
  20. Jeremy V Mathews

    Northwestern University, Chicago, IL, United States
    Competing interests
    No competing interests declared.
  21. Matthew J Schipma

    Quantitative Data Science Core, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0865-1057
  22. Tao Liu

    Biological Sciences Division, Pacific Northwest National Laboratory, Richland, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9529-6550
  23. Valerie L Tokars

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  24. Massimo Cristofanilli

    Department of Medicine, Northwestern University, Chicago, United States
    Competing interests
    No competing interests declared.
  25. Tujin Shi

    Biological Sciences Division, Pacific Northwest National Laboratory, Richland, United States
    Competing interests
    No competing interests declared.
  26. Yang Shen

    Department of Electrical and Computer Engineering, TEES-AgriLife Center for Bioinformatics and Genomic Systems Engineering, Texas A&M University, College Station, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1703-7796
  27. Nurmaa K Dashzeveg

    Department of Pharmacology, Northwestern University, Chicago, United States
    Competing interests
    Nurmaa K Dashzeveg, has patents on exosomes which are not related to this manuscript..
  28. Huiping Liu

    Pathology Core Facility, Northwestern University, Chicago, United States
    For correspondence
    huiping.liu@northwestern.edu
    Competing interests
    Huiping Liu, is scientific co-founder of ExoMira Medicine, Inc and has patents related to exosome therapeutics which are not related to the scientific discoveries of this paper..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4822-7995

Funding

National Cancer Institute (R01CA245699)

  • Erika K Ramos
  • Huiping Liu

National Institute of General Medical Sciences (R35GM124952)

  • Yang Shen

U.S. Department of Defense (W81XWH-16-1-0021)

  • Huiping Liu

Susan G. Komen (CCR18548501)

  • Xia Liu

American Cancer Society (ACS127951-RSG-15-025-01-CSM)

  • Huiping Liu

National Cancer Institute (T32 CA009560)

  • Erika K Ramos

National Cancer Institute (T32GM008061)

  • Emma J Schuster

National Science Foundation (CCF-1943008)

  • Yang Shen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mice used in this study were kept in specific pathogen-free facilities in the Animal Resources Center at Northwestern University. All animal procedures complied with the NIH Guidelines for the Care and Use of Laboratory Animals and were approved by the respective Institutional Animal Care and Use Committees.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,039
    views
  • 537
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Erika K Ramos
  2. Chia-Feng Tsai
  3. Yuzhi Jia
  4. Yue Cao
  5. Megan Manu
  6. Rokana Taftaf
  7. Andrew D Hoffmann
  8. Lamiaa El-Shennawy
  9. Marina A Gritsenko
  10. Valery Adorno-Cruz
  11. Emma J Schuster
  12. David Scholten
  13. Dhwani Patel
  14. Xia Liu
  15. Priyam Patel
  16. Brian Wray
  17. Youbin Zhang
  18. Shanshan Zhang
  19. Ronald J Moore
  20. Jeremy V Mathews
  21. Matthew J Schipma
  22. Tao Liu
  23. Valerie L Tokars
  24. Massimo Cristofanilli
  25. Tujin Shi
  26. Yang Shen
  27. Nurmaa K Dashzeveg
  28. Huiping Liu
(2022)
Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity
eLife 11:e82669.
https://doi.org/10.7554/eLife.82669

Share this article

https://doi.org/10.7554/eLife.82669

Further reading

    1. Cancer Biology
    2. Cell Biology
    Maojin Tian, Le Yang ... Peiqing Zhao
    Research Article

    TIPE (TNFAIP8) has been identified as an oncogene and participates in tumor biology. However, how its role in the metabolism of tumor cells during melanoma development remains unclear. Here, we demonstrated that TIPE promoted glycolysis by interacting with pyruvate kinase M2 (PKM2) in melanoma. We found that TIPE-induced PKM2 dimerization, thereby facilitating its translocation from the cytoplasm to the nucleus. TIPE-mediated PKM2 dimerization consequently promoted HIF-1α activation and glycolysis, which contributed to melanoma progression and increased its stemness features. Notably, TIPE specifically phosphorylated PKM2 at Ser 37 in an extracellular signal-regulated kinase (ERK)-dependent manner. Consistently, the expression of TIPE was positively correlated with the levels of PKM2 Ser37 phosphorylation and cancer stem cell (CSC) markers in melanoma tissues from clinical samples and tumor bearing mice. In summary, our findings indicate that the TIPE/PKM2/HIF-1α signaling pathway plays a pivotal role in promoting CSC properties by facilitating the glycolysis, which would provide a promising therapeutic target for melanoma intervention.

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ananda Kishore Mukherjee, Subhajit Dutta ... Shantanu Chowdhury
    Research Article

    Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.